
    
      This is an exploratory study. PBR28 PET scan is new, promising and exploratory endpoints in
      MS clinical trials, making sample size estimation difficult.

      A separate pre-screening consent form will be issued for the TSPO rs6971 polymorphism and
      eGFR blood samples, a separate pre-screening step. Eligible participants, according to their
      TSPO rs6971 polymorphism will be presented a separate study consent form to continue into the
      clinical trial.

      Study Assessments include 1 PET scan, 1 MRI scan, OCT, EDSS exam, physical exam, cognitive
      questionnaires, etc.
    
  